Sai Life Sciences Sustainability Report 2023

31 Discovery Chemistry, Manufacturing & Controls (CMC) Development Manufacturing Offer a wide range of skill-sets and technologies that go into the drug discovery process and service the customers in different geographies giving access to flexibility and speed. Development: Adept at partnering by handling complex chemistry and tried and tested approach to scaling up and technology transfer. Steadfast in collaborating with customers for climate action, operationalising and continuously evolving our sustainability goals thereby enabling our customers progress with their supply chain related sustainability commitments, successfully manufacturing quality products delivered on-time. We are steadfast in our commitment to ‘being a partner of choice’ for our customers by addressing their needs in the discovery, development and manufacture of the medicines of future in a sustainable manner. At a time when the drug discovery, development and manufacturing cycles are on the fast track in order to meet patient needs, our customers explore ways of de-risking their R&D efforts and increasing the speed to market of their new molecules. To effectively partner, we are taking vital actions to boost efficiency, advance green chemistry practices, building automation tools, adding new capabilities and establishing norms that lead to sustainability being firmly established in our strategy and operations. Forging a path through discovery and into development with the same integrated partner like Sai where a good relationship, expertise and capabilities exist smoothens the path of outsourcing in the life sciences industry. Our sustainability commitment delivered through our business verticals and in the value chain For innovator companies, speed, quality, and cost continue to be critical levers and there is a need to balance these with market expectations and regulatory challenges. This makes them seek advanced supply chain opportunities to optimize the development of their molecules by establishing partnership with CDMO companies. At Sai we combine access to scientific talent, advanced technologies, manufacturing and process excellence which enables the innovator companies improve their capital efficiency while progressing with innovation goals. Discovery Our global delivery model delivers unique value to our customers through an optimal blend of talent, technologies, automation and relentless focus on speed, and cost efficiency. This journey typically starts with our exploratory biology facility in Boston, where we work hand-in-hand with our customers in real-time on early discovery biology programs that are difficult to outsource to India. These programs then transition to the company’s Hyderabad R&D campus, where we have consolidated chemistry, biology and ADME-PK services in one integrated campus, enabling our scientists to work as teams and deliver quality data to the customers. Electrophysiology: Understanding effects of drug better In FY23, we added new capabilities in niche areas such as electrophysiology. In drug discovery process, electrophysiology has the potential to revolutionize both lead-exploration and lead-optimization steps by providing a more accurate and efficient way to assess drug effects on ion channels and receptors. By combining electrophysiology with other advanced technologies, such as high-throughput screening, organoids/organ-on-a-chip, machine learning-based event detection, and iPSCs, researchers can greatly accelerate the drug discovery process and improve the chances of developing effective therapies for a wide range of diseases.

RkJQdWJsaXNoZXIy MTIwMDc4NQ==